What we are looking for

The REPAIR Impact Fund invests in start-ups, early-stage companies and corporate spin-outs. Our philosophy is to support ambitious programmes addressing antibiotic resistance through a broad range of therapeutic modalities.

REPAIR will back companies that we believe can change the future of the antibiotic resistance battle: innovative science, driven by a clear product vision and a strong management team and comfortable in a changing regulatory environment. The investment selection and decision process is supported by our international Scientific Selection Board and will give priority to programmes targeting high-priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention.

At Novo Holdings, we believe that innovation is the key to longer-term success. We will therefore give priority to first-in-class therapies, covering small molecules, biologics and new modalities, from the early stage of drug development (lead optimization) to the early stages of clinical development (Phase 1).

Given the difficult environment for anti-infectives, the REPAIR Impact Fund will keep certain capital in reserve to potentially support funding for its portfolio companies Phase 2 clinical trials.

We are equally comfortable investing as the sole investor or in a syndicate, with convertible loans or royalty-based instruments ranging from USD 1 million to USD 15 million.

SEE LIST OF THE MOST URGENT MULTI-DRUG RESISTENT INFECTIONS

Main Criteria

The first-pass selection priorities will be based on a non-confidential presentation. Companies given priority will then be invited to send a full business plan with an extended presentation of the scientific rationale, available data, budget and development plan, including milestones, to be reviewed by our Scientific Selection Board. Based on the assessment of the Scientific Selection Board, including a question-and-answer process, the finalists will be nominated and invited to present their projects live to the Scientific Selection Board.

Pathogens: from the high-priority list of the World Health Organization and the United States Centers for Disease Control and Prevention
Therapies: first-in-class therapies have priority
Modalities: small molecules, biologics and new modalities
Phases: from the early stage of drug development (lead optimization) to the early stages of clinical development (Phase 1)